A variety of anti-CD33 CAR-T cell constructs have shown significant preclinical therapeutic effects on primary acute myeloid leukemia (AML) cells in vitro and in humanized animal models, and their toxic effects on leukemia cells and non-leukemia myeloid cells have also been observed (111). Here, CD33 is linked to leukemia.